c-tap
C-TAP aims to expand access to COVID-19 technologies and health products.

A new sublicense agreement for a COVID-19 antibody test has been announced Thursday by the Medicines Patent Pool (MPP) on behalf of the World Health Organization’s COVID-19 Technology Access Pool (C-TAP) and South African company Biotech Africa. 

The new agreement builds on the first non-exclusive licensing agreement announced by WHO and MPP last year with Spain’s National Research Council (CSIC). The sublicense allows Biotech to manufacture and commercialize CSIC’s COVID-19 serological test worldwide. The test effectively checks for the presence of SARS-CoV-2 antibodies developed in response to COVID-19 infection or to a vaccine. 

Both WHO and Biotech welcomed the agreement, which will cover all related patents and biological material needed to manufacture the test. Additionally, the license will be royalty-free for low- and middle-income countries and will remain valid until the patent expires. 

“The most effective way to get – and keep – ahead of COVID-19 is to keep testing,” said WHO Director General Dr Tedros Adhanom Ghebreyesus. 

“This new agreement means we can take advantage of untapped manufacturing capacity so more people in more countries can have easier access to affordable diagnostics.”

“The signing of this agreement emphasizes [Biotech Africa’s] ongoing goal to support diagnostic needs around the world,” said Jenny Leslie, Biotech Africa Chief Operations Officer. 

2nd year anniversary of C-TAP comes with challenges and need to incentivize private sector 

Medicines Patent Pool Executive Director Charles Gore

The agreement was announced by the World Health Organization on the second anniversary of the launch of C-TAP – which aims to be a pool for the open-licensing of COVID treatment, vaccine and test technologies. 

C-TAP was launched in 2020 by WHO’s Dr Tedros and the President of Costa Rica with the aim to pool technologies that would boost manufacturing capacity in developing countries, and also expand access to COVID-19 health products. 

The pool mechanism stood empty for nearly a year until Spain announced in November 2021 it would partner with C-TAP over the antibody technology.  In March 2022, C-TAP received a boost from an announcement by the US National Institutes of Health (NIH) that it would share a number of COVID technologies for which it holds the patents.

Celebrating the second anniversary during a virtual event Thursday, MPP Executive Director Charles Gore acknowledged both the challenges C-TAP has experienced in its two years and the potential for more partnerships to be made in the future. 

“Two years on, to be frank, we’ve made progress, but it’s been slow,” he said. 

Gore pointed to the need to find more ways of incentivizing the private sector to share patents.

“It’s unrealistic to expect for-profit organizations to change into philanthropies overnight. We need to think about how to incentivize the sharing of patents and know-how, and how to put that into practice.” 

“Access should not need a pandemic to put it at the top of the health agenda. But now that it has happened, we must at least make the most of this opportunity. And that’s for COVID-19 now, but critically also for the future,” concluded Gore.  

Image Credits: Marco Verch/Flickr.

A health worker explains her child’s symptoms to a mother in a Guinea health centre

On the Day of the African Child, Medicines for Malaria Venture (MMV) reflects on what 10 years of seasonal malaria chemoprevention has meant for young children in the Sahel, and how to protect more children going forward.

Malaria, a disease that is both a cause and consequence of poverty, has plagued endemic-country health systems, economies and people — especially children — for millennia.

The Day of the African Child is an opportunity to celebrate 10 years of seasonal malaria chemoprevention (SMC) and to draw attention to the fact that, despite the progress made against the disease, children in sub-Saharan Africa still bear the majority of the global burden.

The World Health Organization (WHO) first recommended SMC in 2012 to protect eligible children in Africa’s Sahel region, where malaria transmission is at its highest during the rainy season. The importance of this is underscored by the fact that six out of 10 countries targeted by WHO’s ‘high burden to high impact’ initiative are located in this region.

When administered to this population of children in this geographic region, the intervention has been shown to be highly effective, providing up to 88% protection against malaria within the first 28 days after its administration and reducing hospital admissions by up to 39%.

Modelling estimates also suggest that the intervention could curb roughly 21 million malaria cases and prevent 100,000 child deaths each year, if successfully delivered to at-risk populations. National malaria control programmes (NMCPs) have therefore been quick to include SMC in their strategic plans and deliver it year-on-year.

To administer SMC, children aged three to 59 months receive one dose of sulfadoxine-pyrimethamine with three doses of amodiaquine (SPAQ) 3 days a month. Previously, this was recommended for up to four months; however, WHO’s new guidelines recommend SMC for the “peak malaria transmission season”, regardless of length.

SMC use has expanded rapidly since its introduction. In 2012, several thousand children in two countries received SMC. In 2021, about 44 million children in 13 countries benefited. The growing number of children receiving SMC required greater supply security and more pharmaceutical suppliers.

Fosun Pharma’s subsidiary, Guilin Pharmaceuticals, with MMV’s support, developed a SPAQ tablet that was prequalified by WHO in 2014. Results from the first SMC trials showed that the intervention would be more effective if the medicines were palatable and easily dissolved in water, reducing the likelihood that children would spit them out.

Consequently, Guilin developed a child-friendly version of SPAQ that was prequalified by WHO in 2018. MMV and S-Kant, funded by UNITAID, developed another dispersible version of SPAQ that was WHO prequalified in 2021. Since 2014, over 700 million treatment courses of SPAQ have been distributed.

Relieving pressure on health systems and economies

A local health center during coronavirus.

Currently, the malaria burden in sub-Saharan Africa is an impediment to reaching Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages), and more specifically, Target 3.3 (End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases).

SMC is a low-cost intervention that contributes to reducing the burden on health systems in terms of cost of malaria diagnosis, treatment and in-patient admissions. In fact, a 2021 analysis in seven countries revealed that implementing SMC saved health systems approximately USD 66 million and increased economic productivity by USD 43 million, contributing to Goal 8 (Decent work and economic growth).

This is also significant for families who pay out of pocket for malaria diagnosis and treatment: 13% of the global malaria budget came from out-of-pocket expenditure; much higher than with other priority diseases in sub-Saharan Africa such as HIV/AIDS, where out-of-pocket expenditure represented just under 5% of global spend.

Integrating SMC and other health interventions

Seasonal malaria chemoprevention has saved thousands of lives of children under the age of five.

Combining SMC with interventions such as malaria community case management (CCM), long-lasting insecticidal net distribution and malnutrition interventions has enabled health systems to optimize staff time and reach children who otherwise may not have been reached.

Even with limited resources, through CCM, countries have trained and supported community health workers who provide services for multiple illnesses such as malaria, pneumonia and diarrhoea for sick children and families with limited access to case management at health facilities.

In 2021, WHO approved the RTS,S vaccine for children in areas with moderate to high Plasmodium falciparum malaria. While the vaccine is a useful addition to the malaria control toolbox, its efficacy (around 36%) falls short of being a silver bullet. Encouragingly, recently reported studies have shown that when the vaccine is combined with SMC, the efficacy in preventing malaria is significantly greater for each intervention alone – providing a belt-and-braces approach to better protect young children at risk of malaria.

The introduction of innovations like digital tools, which are replacing paper-based data collection and management systems in SMC campaigns in Benin, the Gambia, Ghana and Nigeria, has also helped better manage and improve data quality. Enhancing the integration of digital systems will contribute to stronger data management systems that can provide evidence for informing policy decisions and boosting programme effectiveness.

Initiatives such as the European & Developing Countries Clinical Trials Partnership-funded OPT-SMC project are also building NMCP staff’s capacity to better implement SMC and improve data monitoring, evaluation and management in all 13 implementing countries.

Overcoming new challenges and finding ways forward

Boys drink water from rehabilitated wells by AMISOM in EL-Ma’an, Bal’ad District of HirShabelle State.

Now that protection of children under 5 in the Sahel is improving, there is evidence of seasonal malaria shifting to older children. Projects in Senegal have shown that SMC is effective in five- to 10-year-olds. Consequently, the SMC-Impact project, financed by the Korea International Cooperation Agency’s Global Disease Eradication Fund, will pilot expanding SMC to older children in the Gambia and Niger.

While the numerous benefits of SMC for communities and economies are evident, children in parts of Southern and East Africa with seasonal malaria are not yet benefiting from the intervention due to anticipated lack of efficacy due to high levels of resistance to SP and AQ, which have precluded large-scale implementation.

However, preliminary results from pilots conducted with SPAQ in Eastern and Southern Africa show positive results. Additionally, the updated WHO guidelines for malaria chemoprevention suggest that any antimalarial combination that is different from those used for first-line treatment can be used for SMC. Thus, larger-scale implementation of SMC can be anticipated in Africa in the coming years.

Despite proven benefits, the future of SMC is uncertain, as malaria budgets continue to be under threat due to growing health and national security challenges facing both donor and SMC-implementing countries. Africa’s growing population, which is expected to triple by 2100, will require protection against malaria.

In addition to saving lives, protection against life-threatening diseases like malaria will bring significant productivity and economic benefits. Increased financing and national stewardship for SMC are non-negotiable if countries want to keep populations healthy and generate national economic savings.

Although there are challenges to reaching all at-risk children, it is important not to overlook the work that has been — and continues to be — undertaken by NMCPs, researchers, healthcare workers and caregivers to save children’s lives over the past 10 years. The impact of SMC has been remarkable, and in the decade ahead, it will likely increase the impact it can deliver as restrictions on geography and targeted age ranges are relaxed.

Dr Abena Poku-Awuku is an Advocacy Manager at Medicines for Malaria Venture. Dr André-Marie Tchouatieu is a Director of Access and Product Management at Medicines for Malaria Venture.

Image Credits: Medicines for Malaria Venture, USAID.

Russia’s ongoing refusal to let Ukranian grain lift its blockade of Black Sea ports is causing a global food crisis and has led to allegations that the country is weaponizing” the world’s food supply.

Over the weekend, Ukrainian President Volodymyr Zelenskyy warned that the world will face a “severe food crisis” as Russia’s war continues in his country. 

“The world will face an acute and severe food crisis and famine,” he said, virtually addressing 575 delegates from 40 countries at the Shangri-La dialogue in Singapore, Asia’s top defense conference.

At the beginning of June, Senegalese President Macky Sall and chair of the African Union Chair, announced that Russia had told him it was ready to allow Ukrainian grain exports.

Last week, Sall urged Ukraine to de-mine waters around its Odessa port to ease much needed grain exports from the war-torn country on the basis that Russia has said it will not attack the ports – something Ukraine is not ready to believe.

Meanwhile, there are various reports that Russia has been stealing grain from some of the ports and selling it elsewhere, but this has been denied by Russia.

Ukraine and Russia produced 30% of the world’s grain. 

Russia has also seized wheat, bombed silos and many railways, with Ukrainian Ministry of Foreign Affairs spokesperson Oleg Nikolenko noting that “Russia’s appetite was growing” as it destroyed the second biggest grain terminal in Ukraine on 7 June.

“The food [crisis] touches Asia, Europe and Africa. Russia has blocked the Black Sea. Prices are rising. Russia is violating international law,” Zelenskyy added, following his remarks at the dialogue. 

Ukraine has asked Europe for temporary storage in an effort to secure the next harvest, with Deputy Agriculture Minister Markian Dmytrasevych highlighting that Russian occupation in the south and east has reduced the country’s grain storage capacity by 15 million tons, in a tweet from the Ukrainian Kyiv Independent. 

As reported by Reuters, Russia’s foreign minister Sergei Lavrov has said that it is Ukraine’s responsibility to solve the problems of resuming grain shipments, adding that Moscow has fulfilled its necessary commitments. 

Africa feels the pressure of food shortage 

food shortage
As the impact of drought worsens, growing risk of famine in Somalia, in combination with hiked food prices from the Ukrainian food shortage. 
Some 4.5 million Somalis are directly affected by the drought, and about 700,000 people have been displaced.

Africa already acutely feels the ripple effects of the war in Ukraine.

A combination of drought in the Horn of Africa and hiked food and fuel prices have left poor families out of reach of food, in addition to killing crops and livestock. North Africa and the Middle East have already experienced a 70-80% increase in the price of wheat, a staple food in this region. 

Both the United Nations and the US have addressed the resounding impact of the global food crisis.

“The Kremlin needs to realize that it is exporting starvation and suffering well beyond Ukraine’s borders, with countries in Africa that are experiencing an outsized share of the pain,” said Antony Blinken, US Secretary of State, in his remarks during a 6 June roundtable discussion on food security. 

“The prices in the world are going up. We see in some countries up to 17 percent of inflation. We see shortages of food in many parts of the world, especially in the Sahel of Africa, the Horn of Africa and other populous countries that depend on wheat as a staple food,” said Amin Awad, UN crisis coordinator, to Rosemary Barton Live. 

“If the world does not widen its gaze from the war in Ukraine and act immediately, an explosion of child death is about to happen in the Horn of Africa,” Rania Dagash, deputy regional director of UNICEF, told a briefing.

About 49 million people are at risk of falling into famine conditions in the months ahead, according to a Hunger Hotspots report published last week by the UN Food and Agriculture Organization (FAO) and World Food program. 

“The war in Ukraine has exerted an upward pressure on already elevated food prices, with major effects on acute food insecurity,” the report reads. 

For the Horn of Africa in particular, the Somali peninsula has 386,000 children in urgent need of treatment for life-threatening malnutrition, up from the 340,000 children who needed treatment in 2011, a year when famine killed hundreds of thousands of people. 

Somalia is “on the brink of devastating and widespread hunger, starvation and death,” warned Dagash. 

“[This is a] perfect storm for famine if action is not taken now.”

Image Credits: Joseph C. Okechukwu/Twitter , UN-Water/Twitter .

WTO Director-General Dr Ngozi Okonjo-Iweala at the opening of the 12th WTO Ministerial Council

After nearly 18 months of debate, World Trade Organization (WTO) members now appear likely to approve a limited waiver of patent rights on COVID-19 vaccines in their closing session on Wednesday. 

But if the current draft text is approved as it stands, it may be a pyrrhic victory for the medicines access groups that fought for months for a broad waiver of intellectual property (IP) rights on medicines, tests and vaccines, first proposed by India and South Africa in October 2020.  

Those civil society advocates are nervously eyeing the draft waiver’s provisions, which they fear could even set a bad precedent for future accords – a precedent worse than the limits currently contained in the WTO’s Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). 

TRIPS sets out a global set of rules under which countries may break patent protections and issue “compulsory licenses” for urgently needed health products without risk of a formal complaint of trade violations being lodged at WTO.     

“I think we’d arguably rather walk away,” said Jamie Love, director of Knowledge Ecology International, at a press briefing on Tuesday.  “And I think there’s some in pharma that would prefer that too” he added, referring to the longstanding opposition by pharmaceutical groups to the waiver proposal. 

Scope: limited only to vaccines 

The biggest criticism from civil society about the decision likely to be adopted Wednesday is that the waiver is limited to COVID-19 vaccines, now in surplus, while omitting reference to tests and treatments where access is often more uneven.  

Potentially, the waiver’s provisions could be extended in the future to tests and treatments, but text explicitly stating that remained in brackets as negotiations over the final details continued Tuesday evening.   

Speaking at a WHO press briefing Tuesday, WHO’s Director-General Dr Tedros Adhanom Ghebreyesus echoed the civil society frustrations about the dramatically pared-down scope of the waiver text.

“As I have said many times, the TRIPS waiver was created for use in emergencies. So if not now, then when?  I hope countries will come to an agreement on a waiver not just for vaccines, but for diagnostics and therapeutics as well,” said Tedros. 

Worries about new legal precedents 

Civil society groups demonstrate outside embassies of the United States, United Kingdom, Australia, Canada, Brazil, and other countries which oppose a temporary WTO patent waiver on COVID-19 health products.

But other nuances in the near-final waiver text are even more of a concern for the civil society legal experts who follow WTO closely.  

Love and medicines access activist Ellen t’Hoen of Medicines, Law and Policy, described their concerns in a press briefing Tuesday. In particular they noted: 

  • Contrary to existing WTO TRIPS exceptions, only  “developing countries”  can take advantage of the new COVID vaccine waiver formula to import vaccines, potentially excluding lower-middle or middle-income countries that don’t have that status at WTO.   
  • The waiver formula is likely to limit, either explicitly or implicitly, those countries that can export vaccines under a compulsory license to producers with less than 10% of the world’s COVID vaccine export capacity.  In particular, that would exclude China, one of the world’s biggest exporters of medicines and vaccines.  

Those two provisions worry advocates for the precedents they could set. Even under the imperfect system of WTO’s existing TRIPS rules, any country – developed or developing – may opt to manufacture a health product under a compulsory license for urgent public health purposes. And any country may export their products – even if that export is sharply curtailed by a host of bureaucratic rules around packaging and notification to WTO, enshrined in a famous 2005 TRIPS amendment, known as 31 bis.    

What’s good about the waiver?

The one potential “improvement” in the waiver language, medicines access advocates say, is that reference to those “notification” requirements, as required under 31 bis have been streamlined somewhat.

Whereas under the existing rules, countries producing and exporting a health product under a compulsory license have to notify WTO officially of its moves ahead of time, the language in the IP waiver for COVID-19 vaccines states that such notification may take place “as soon as possible after the adoption of the measure.”

Since formal notifications of any kind to WTO typically take place at ministerial level, it can slow down exports immensely, Love noted.  “You can’t just talk to the Minister of Health, for example.

“You’re going to have to talk to the Minister of Trade. They’re going to go to the Foreign Affairs Minister if it’s  a WTO notification. 

“It may just be an email. But that email doesn’t just zip out the door. I mean, anytime that the WTO is invoked, it’s a high level of coordination within multiple government departments, including people with very different political views on things. 

“Often this involves four cabinet-level ministers in the exporting country and another four in the importing country.  So say you’re trying to run a business and you’re trying to get like maybe four Cabinet members in two different countries every time you change your order to sign off on something and notify the WTO. Not an easy process.

“And they [the trade and foreign affairs ministers] have counterparts in the United States, in Europe, for example, that they care about and they have relations with, and that just opens up and multiplies the areas for bilateral pressure, or maybe just inaction. 

Ellen t’Hoen

Waiver doesn’t enable know-how sharing

Another oft-stated goal, at least indirectly, of the waiver measure, was to stimulate local manufacturing in countries that lacked means to buy vaccines abroad as well as the political or financial capacity to strike investment deals with major pharma companies on local production.  

Those gaps were most evident in African countries that were almost entirely shut out of the first months of vaccine roll-out after India banned exports of AstraZeneca’s COVID vaccines produced by Indian generic companies during the height of its pandemic, the sole supplier of vaccines for the global COVAX platform.

Perhaps it was partly as a result of political pressure around the waiver, that major pharma companies like Moderna and Pfizer eventually reached out voluntarily to strike a range of new deals with African manufacturers on COVID vaccine production. 

But pharma groups always maintained that the waiver could not compel vital sharing of know-how or even generate “one more dose” of vaccines.  

While Love and other access advocates still believe that the initial proposal for a broad-based waiver on all COVID health products, affecting not only patents but also trade secrets and know-how, could have triggered more transformational changes, they now are grudgingly in agreement with the idea that the WTO decision, as it stands now, will have little real impact. 

“If you want the vaccine, you need a certain level of collaboration, a sharing of that technology,” said t’Hoen. “WHO has tried to facilitate that through the technology access pool… But it’s much more important to have that know-how in the public domain at an earlier stage, so that it can be managed much earlier.”

The limited waiver process has snowballed, and will likely be carried forward Wednesday largely by ministers who need to show a political result out of the WTO, which critics have accused of being more and more irrelevant anyway. 

Meanwhile, Love and his allies are setting sights on new initiatives and formulas to shake up the trade body, one being a “public goods” platform where countries could commit under existing WTO rules to ensure that its public funding for new health-related R&D contains formulas for open-licensing of resulting medicines or vaccines innovations – or at the least, the open publication of trial results and research findings. 

A new WTO initiative on public goods

“I hope the WTO will walk away from the train wreck that this is and start working on the global good agreements,” said t’Hoen. 

“We hope that between now and the next ministerial..  more than one government will table a text on an agreement with the WTO on public goods,” added Love, noting that such an agreement could be modelled on the existing WTO “General Agreement on Trade and Services”. 

Trade-related “public goods” pledges made under the proposed mechanism would be binding, make use of the existing WTO dispute resolution processes, and could also be used to promote “public goods” well beyond medicines – from trade measures that advance climate mitigation or biodiversity to food security and refugee relief.  

“We think this would be a good project for the WTO… It would change the culture of the WTO and it would be a service to the public … It would get governments to sponsor and mobilize public goods, to put them on their agenda. 

At the same time he admits that, in terms of the IP waiver battle, he frames it as a chapter that may be closing for now, for better or worse: 

“I think that it has been overstated what the effect of the WTO rules are. The WTO doesn’t grant patents or enforce patents. If it disappeared tomorrow, it wouldn’t change any existing IP granted under national law, bilateral or regional agreements,” said Love.

 

Image Credits: Samy Rakotoniaina/MSH, Jay Louvion/ WTO, Tadeau Andre/MSF .

Monkeypox lesions

Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), has called a meeting of the emergency committee for next Thursday to discuss whether monkeypox should be declared a public health emergency.

This follows the spread of the disease in at least 32 new countries outside of the nine African countries where it is endemic, with 1,600 confirmed cases and a further 1,500 suspected cases reported to the WHO.

“The global outbreak of monkeypox is clearly unusual and concerning. It’s for that reason that I have decided to convene the Emergency Committee under the International Health Regulations next week to assess whether this outbreak represents a public health emergency of international concern,” Tedros told a media briefing on Tuesday.

The WHO has described the identification of over 1,200 confirmed cases of monkeypox in just over three weeks as “an unprecedented event”.

There have been 72 deaths reported this year, all in endemic countries, although the WHO is investigating a possible monkeypox death in Brazil.

“While in the current outbreak most but not all initially reported cases from four WHO regions are among persons who self-identify as men who have sex with men, it is expected that other cases will continue to occur in different population groups,” according to WHO’s vaccine and immunization guidance on monkeypox published on Tuesday.

Renaming monkeypox?

Dr Rosamund Lewis, WHO technical lead on monkeypox

The WHO is also discussing changing the name of monkeypox and its clades, currently known as the Central Africa and West Africa clades.

The WHO is also in discussion with member states about “equitable access” to the smallpox vaccine for monkeypox.

However, WHO monkeypox technical lead Dr Rosamund Lewis warned that while some smallpox vaccines may be protective against monkeypox, a lot of the data is old or relates to animal studies.

“There was not a lot of clinical data and so WHO is calling on countries to work together to collaborate in the use of these vaccines, and to use standard research protocols with standard data collection tools so that we can learn about the effectiveness of vaccines as they are deployed in this situation,” said Lewis.

The WHO does not advocate mass vaccinations but says rather that decisions around immunization with smallpox or monkeypox vaccines should be made on a case-by-case basis through “clinical decision-making, based on a joint assessment of risks and benefits” between a health care provider and a patient.

“Control of monkeypox outbreaks primarily relies on public health measures including surveillance, contact-tracing, isolation and care of patients,” according to the WHO guidelines.

A recent two-day scientific meeting on monkeypox convened by the WHO identified a number of research priorities including whether the disease is spread by people who are asymptomatic and whether those vaccinated against smallpox have lifelong immunity to monkeypox.

Grade three emergency in Horn of Africa

Drought-affected livestock walking to a river in Adadle district in the Somali region of Ethiopia.

The WHO has declared a “grade three emergency” – the highest level possible – in the Horn of Africa, “where the worst drought in 40 years has pushed over 30 million people in eight countries into acute food insecurity,” Tedros said. 

Among the affected countries – Djibouti, Eritrea, Ethiopia, Kenya, Somalia, South Sudan, Sudan and Uganda – an estimated 7.5 million people have left their homes in search of food and water.

‘A grade three emergency means that we are on coordinating the response across all three levels of the organisation: country offices, regional offices and headquarters,” said Tedros. “Our priorities are supporting countries to find outbreaks and to make sure people have access to the essential health services they need.”

Last week, UNICEF reported the 2022 March-May rainy season was “likely to be the driest on record, killing livestock and crops, displacing populations, increasing the risk of disease and malnutrition, and pushing children and families to the brink of death or destitution.”

“Communities are taking extreme measures to survive, with thousands of children and families leaving their homes in pure desperation in search of water, food, and pasture, requiring a collective response by all humanitarian partners,” said UNICEF. “This is a water crisis and more than 8.5 million people, including 4.2 million children, are facing dire water shortages in the region.”

Tedros said there were severe implications for public health.

“Malnourishment can have a lifelong impact on health and makes people increasingly vulnerable to disease,” he said. “Severely malnourished children are nine times more likely to die of this, such as cholera and measles.”

Image Credits: Tessa Davis/Twitter , Michael Tewelde / World Food Program.

Earlier in the pandemic, some travellers donned protective plastic jackets at Hong Kong airport.

Travellers entering the US from other countries no longer need negative COVID-19 tests, Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC) announced on Sunday.

The CDC continues to recommend that all people stay up to date with COVID-19 vaccinations and wear masks on public transport.

From Saturday, 11 June 2022, all COVID-19-related restrictions for entry into Germany were also preliminarily lifted, meaning that no proof of vaccination, recovery or testing is required.

Meanwhile, Canada has suspended mandatory random testing of  COVID-19 for international travellers at its airports during the month of June, saying that it is preparing to take this testing “off site”.

“There is no change for air travellers who do not qualify as fully vaccinated. Between June 11 and June 30, these travellers will continue to be tested on arrival at the airport and on Day 8 while they quarantine for 14 days,” Health Canada and the Public Health Agency of Canada announced.

Random testing has caused substantial delays at Canadian airports, particularly as more people resume travel.

 

Canadian President Justin Trudeau announced on social media on Monday that he had tested positive for COVID-19, adding that “I feel okay, but that’s because I got my shots. So, if you haven’t, get vaccinated – and if you can, get boosted.”

South Korea lifted its seven-day quarantine mandate for unvaccinated arrivals from overseas on 8 June. All travellers, regardless of vaccination status, still need a pre-departure Covid test and a PCR test within three days of arrival.

China still requires all international travellers to be screened for COVID-19 on arrival and subjected to at least 14 days of quarantine, some of it in designated government quarantine sites.

Similarly, travellers to Hong Kong need to provide a negative test and hold a reservation in a designated quarantine hotel.

All vaccinated travellers must undergo COVID-19 tests on arrival in Hong Kong and wait for a negative result before continuing to their quarantine hotel, where they can leave after a week if they have had two successive negative tests on days five and seven. Unvaccinated travellers face a 14-day quarantine but can also have this cut to seven days following two successive negative tests.

 

Image Credits: WHO Africa.

international labour conference
Renate Hornung-Draus, delegate of Germany at 110th session of the International Labour Conference

The principle of a safe and healthy working environment has been adopted to be included in the International Labour Organization’s (ILO) Fundamental Principles and Rights at Work in a landmark decision during the annual International Labour Conference (ILC).

The International Labour Conference, held 27 May – 11 June, brings together delegates from ILO member states that represent governments, workers and employers to establish and adopt international labour standards.

Delegates adopted the measure at the Conference’s plenary sitting on Friday 10 June. 

Until now, there have been four categories of Fundamental Principles and Rights at Work:

  • Freedom of association and the effective recognition of the right to collective bargaining;
  • Elimination of all forms of forced or compulsory labour;
  • Effective abolition of child labour;
  • Elimination of discrimination in respect of employment and occupation.

The decision by the Conference means that Occupational Safety and Health will become the fifth category, with delegates celebrating the landmark addition. 

“The solid confirmation of a safe and healthy working environment by including it as a fifth pillar into the 1998 declaration reconfirms that all ILO members need to step up their work on the realisation of a safe and healthy working environment,” said Renate Hornung-Draus, delegate of Germany, speaking at the plenary on Friday.

“Ever since the adoption of the ILO Constitution in 1990, the pursuit of the protection of the life and health of workers has featured prominently in the work of ILO,” said Amos Kuje, delegate of Nigeria. 

“The ILO and its members will be in a better place to pursue it with greater legal effectiveness in the future. The life, health, and well-being of millions upon millions of workers depends on this [resolution]. We have to rise to the challenge.”

The ILO had published a joint report with the World Health Organization last September 2021 on work-related burden of disease, finding that diseases associated with long working hours and workplace injuries accounted for the top two causes of worker deaths. This report, the first global comparative risk assessment on work-related burden of disease, led to calls from both organizations to use the findings of the report to shape policies and practices that created healthier and safer work environments.

Creating inclusivity at work for vulnerable populations a focus of the International Labour Conference 

Women on their way to work in Raipur, India.

Earlier that day, the ILC held its high-level World of Work Summit tackling multiple global crises and promoting human-centered recovery and resilience, with specific focus on an urgent need to address the labour and social consequences of current crises, and creating an inclusive environment, particularly for vulnerable populations. 

“While the picture is bleak and the outlook uncertain, we must not lose sight of our vision for a better future of work. The hopes and dreams of millions depend on us. We cannot let them down. Together, we must deliver on our promise of a better, fairer, more inclusive, future for all,” said ILO Director-General Guy Ryder at the opening of the Summit. 

“We must renew our efforts to create decent work opportunities, especially for the most vulnerable groups,” he added.

President Wavel Ramkalawan of Seychelles and President Xiomara Castro of Honduras called for better work protections for women and children. “Our message should be one of hope,” said Ramkalawan. “Our actions and policies should present hope for our people, while we fight the scourges of corruption, exploitation and injustice,” 

Image Credits: ILO, Prem Kumar Marni/Flickr.

WTO Ngozi Okonjo-Iweala speaking just ahead of the opening of the 12th Ministerial Conference of WTO on Sunday.

The World Trade Organization’s Director General Dr Ngozi Okonjo Iweala said she was “cautiously optimistic” about the potential for WTO members to reach long-delayed agreements on issues such as a limited IP waiver for COVID vaccines as well as a decision to curb harmful fisheries subsidies that allow big industrial rigs to plunder the oceans  – depleting global fish stocks and harming food security for billions of people. 

Iweala spoke at a press briefing Sunday just ahead of the opening of WTO’s long-delayed 12th Ministerial Conference (MC12) that afternoon. The conference in Geneva, the first ministerial meeting in five years, will consider a newly-published draft text that would end subsidies to long-range fishing fleets operating on the “high seas”. The draft text also would require countries to  invest in oceans maintenance to preserve fish stocks in coastal waters, offset any subsidies they may continue to offer.  

MC12 also will attempt to finalize a long-disputed agreement on a limited waiver on intellectual property for COVID vaccines. And in response to the global food security crisis triggered by Russia’s war in Ukraine, members will will consider a draft ministerial decision exempting the World Food Programme from export restrictions on agricultural products – levied by many countries in the wake of the halt to exports of Ukranian and Russian food and agricultural inputs. 

Civil society groups, however, protested being locked out of the physical conference corridors on opening day, saying that the last-minute move by WTO, ostensibly on security grounds, had “sidelined” voices of dissent at the meeting, being attended by over 100 trade ministers.  

Iweala – ‘You have to get us over the finish line’

Director General Ngozi Okonjo Iweala next to co-sponsor Kazakhstan’s MC12 Chairman Timur Suleimenov

In her formal statement at the conference’s ceremonial opening, Iweala urged WTO members to move ahead assertively on the wide range of issues before them – and thus ensure the continued relevance of the global trade body to multilateral policy-making. 

“Strengthening the multilateral trading system is a global public good that we have collectively and carefully built up over 75 years,” Iweala said. Her speech set out key points of focus for the debates of the next three days – around agriculture and food security, as well as draft agreements on fisheries subsidies and a waiver on some WTO TRIPS provisions on the use of intellectual property – for the purpose of COVID-19 vaccine production. 

“I hope as ministers you can work even better together to complete nearly completed deliverables. So this organization can be put back on a result focus trajectory,” she urged, noting that the fisheries decision has been over 20 years in the makaing.   

On the much discussed IP waiver – as well as a companion  “trade and health” draft declaration reducing barriers to trade in essential medicines and inputs, Iweala urged ministers to “please let’s do it.

“You have to  get us over the finish line. Get us an agreement on the response to the pandemic…  for millions of people to access affordable vaccines and  medical countermeasures – in this and future pandemics.”   

Critics say IP waiver language verging on irrelevance

Critics on both sides of that debate, however, slammed the draft version of the IP waiver text -although the final text of that has not yet been formally released by WTO.  But it is said to be based on a so-called “outcome document” published in May after weeks of final negotiations by co-sponsors India and South Africa along with the European Union and the United States.

See related story here:

After Months of Deadlock, WTO’s TRIPS Council Will Finally Discuss Intellectual Property Waiver Compromise

Some medicines access advocates have even suggested that countries should walk away from the text, which has been limited in scope to only to vaccines and not treatments. Critics also say they fear that the language of the new “waiver” could subtly undermine existing WTO flexibilities enshrined in the original 1994 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), and the 2001 Doha Declaration, which together allow countries to issue “compulsory licenses” for vaccine production in times of public health emergency.

Said Jamie Love, director of Knowledge Ecology International the new TRIPS waiver proposal in fact “includes the most restrictions [to date] on which countries can import or export vaccines.  No other agreement placed restrictions on which countries can export vaccines under a compulsory license, but this one does, excluding most countries that currently have vaccine manufacturing capacity.” He was speaking at a civil society press briefing earlier Sunday.    

Pharma opponents, meanwhile, say the IP waiver would inhibit innovation at a time when low- and middle income countries are facing a surfeit of vaccines that they cannot absorb  – rather than the dearth experienced in the first phase of the 2021 rollout. 

“Today, it is widely accepted that the issue is not vaccines but vaccinations,” said Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), in a comment to Health Policy Watch. He added that for the past year, the “real challenges” have been more around trade and supply side barriers. “So it is really puzzling why so much energy is going into a waiver that we don’t need and has and will do little to tackle its stated aim, e.g. vaccine equity.  

“A TRIPS Waiver on vaccines would never have contributed to a single more vaccine – for that you need voluntary know-how sharing and tech transfer – but it would do harm to future pandemic preparedness because of the signal it sends.”

Fisheries  – can a deal finally be reached ? 

The draft fisheries text has, on the other hand, is being promoted by WTO as a deal that is indeed inching closer to the finish line – with broad buy-in.

And it has been welcomed by a broad array of environmental NGOs, such as the World Wildlife Foundation, as well as by former US trade ambassadors from both Democratic and Republican parties for its long-overdue moves to protect ocean fish stocks, 90% of which are fully exploited, over exploited or already depleted, according to the UN Food and Agriculture Organization. 

The draft text represents the fruits of more than 20 years of negotiations over an estimated $35 billion annually doled out by governments in fisheries subsides.  About $22 million, or two-thirds of those subsidies directly contribute to the depletion of global fish stocks, harming food security and nutrition, recent studies say. The risks are particularly grave for people in low– and  middle-income coastal communities across Africa and Latin America, highly dependent on local fish protein for healthy diets. 

Coastal fishermen and women in those same communities have also seen a depletion in their catches, and thus livelihoods, with no means to compete with big industrial rigs scraping the ocean floor just outside of their territorial waters – and then selling the fish to wealthy nations on global markets. More than 820 million people depend on fisheries and aquaculture for food, nutrition, and income, according to FAO.

“The agreement is not everything we might have wanted. It’s not everything anyone wanted, and that’s the nature of negotiations. But it is a remarkable achievement. It goes beyond anything that has been agreed previously on this topic,” said Alice Tipping, of the International Institute of Sustainable Development, speaking at a Sunday morning press briefing on the fisheries issue, co-sponsored by IISD and WWF, among others. 

Key to the draft agreement are prohibitions on subsidies that enable fishing outside a country’s national waters, incuding “a standalone prohibition on subsidies for fishing in the unregulated high seas, and those apply to all members equally.” The text also requires that future subsidies within a country’s territorial waters be accompanied by fish and ocean management measures to preserve stocks – with a proposed 7-year transition period for low- and middle-income countries to develop and invest in such management systems. 

Agreement still faces rough waters 

Shailendra Yashwent, senior advisor with Climate Action Network

Even so, the agreement still has rough waters to navigate to final approval, with some developing countries like India, as well as some civil society groups protesting its provisions as being tilted towards rich countries that have ample money to spend on oceans management to offset their continued high subsidies.

Dveloping countries need longer than the seven years proposed in the text to transition to new ocean management formulas, the critics say, even if those aim at ensuring the long-term maintenance of fish stocks and oceans health. Removing subsidies too rapidly could harm “artisanal fisheries” in poor countries, that rely on very small handouts for subsistence livelihoods, they add.

Developing countries subsidies, per capita, also are miniscule in comparison to those in developed countries, pointed out  Shailendra Yashwent, a journalist and senior advisor with the Climate Action Network, who also spoke at the fisheries press briefing. 

“India gives only $141 million USD as total subsidies to the sector, which means the subsidy for (an Indian) fishermen is approximately $14 per year per annum, which is nothing compared to $4,956 in the USA, $8,358 in Japan and a hopping $31,800 in Canada,” he pointed out, “and many of those [Indian fishermen] involved in the trade are permanently impoverished.  

“So like the carbon space argument in climate negotiations, the India government says that it wants the countries that have provided huge subsidies for unsustainable fishing in the past to first take the responsibility for significantly cutting down.  

At the same time Yashwent cautioned against attempts by India or other developing countries to throw out the agreement so long overdue: “It is really my hope that middle path has found that India does not block negotiations while protecting the interests of small scale fishermen. 

“India’s position, I truly believe, should not be at the cost of an agreement that is already 22 years in making. And any delay now will allow the industrial fishing fleets of rich nations to wipe out the remaining marine life and cause an irreversible collapse of marine systems and the humanity that depends on it.”

Unsustainable agriculture subsidies, plastics pollution – advancing dialogue 

Timur Suleimenov, chief of staff of the president of Kazakhstan, which is co-hosting MC12

This week’s conference also aims to set out frameworks for future dialogue on, and potentially negotiations over, other looming, environmental health issues that touch the WTO such as: how global trade rules are enabling the burgeoning plastics and environmental pollution of land and water resources; billions of dollars in agricultural subsidies that harm climate and biodiversity; as well as the even more challenging task of reforming trade rules around fossil fuel subsidies, currently estimated to be about $5.9 trillion annually. 

But the focus at this MC12 on those themes, at least for now, will be more around building long term collaborations and understandings – rather than negotating potentially binding decisions, one observer told Health Policy Watch: 

“They represent important opportunities to identify ways forward on a range of trade, environmental and sustainable development issues.”  

Cross-cutting to all of the talks will be the challenges of ensuring the future viability of a rules-based system for global trade – to which leading countries adhere despite the war in Ukraine that has sharpened the already yawning geopolitical chasm between big and emerging powers, including the United States, China, Russia, and India.

Said Timur Suleimenov, chairman of the conference originally to have taken place last year in Kazakhstan, and which the country is now co-hosting in Geneva. “Over the next three days, the world’s eyes are on the WTO.”

Chinese wet market

The first report by the new WHO-convened expert group, Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) has fanned the flames of controversy over evidence about whether a lab leak or a natural “spillover” of the virus from animals to humans was the most likely source from which the COVID pandemic emerged – although in fact it contains little new information on either. 

The preliminary SAGO report, published Thursday, is significant in that it redresses some of the perceived pro-China “biases” of WHO’s first report by an international group of experts on the virus origins issued in March 2021.  

The report marks the first formal acknowledgement by a WHO-sponsored expert group that a possible biosafety failure in the Wuhan Virology Institute should be further investigated as the pandemic trigger – stating: “it remains important to consider all reasonable scientific data that is available through published or other official sources to evaluate the possibility of the introduction of SARS-CoV-2 into the human population through a laboratory incident.” 

The lab escape theory was something the previous WHO international expert group that also visited Wuhan China in January 2021, had discounted as “extremely unlikely” – provoking a political and scientific uproar by critics who said that group lacked adequate biosafety expertise or evidence to draw that conclusion, and had been politicized by its Chinese participants.  

The new WHO report also calls attention to the continuing political barriers to studies that get at the roots of the SARS-CoV2 narrative – including the lack of access to individual patient data and blood samples from tens of thousands of confirmed and suspected SARS-CoV2 cases from late 2019 and early 2020 that China has refused to share, as well as a lack of comparable data from animal studies.  

No intermediate host or spillover event clearly identified

Blyth’s Horseshoe Bat (Rhinolophus lepidus)
Location: Bandhavgarh National Park, Umaria, Madhya Pradesh, India

The committee confirms long-stated claims that the virus originated in bats, “with the closest genetically related viruses being beta coronaviruses, identified in Rhinolophus bats in China in 2013 (96.1%) and Laos in 2020 (96.8%). However, so far neither the virus progenitors nor the natural/intermediate hosts or spill-over event to humans have been identified. 

“Early investigations suggested that the Huanan seafood market in Wuhan played an important role early in the amplification of the pandemic with several of the patients first detected in December 2019 having had a link to the market and environmental samples from the market testing positive…. 

However, the report also concludes that  “the source of SARS-CoV-2 and its introduction into the market is unclear and it is yet to be determined where the initial spillover event(s) occurred….  Furthermore, follow-up studies to identify possible animal sources from which the environmental contamination could have originated have not been completed.” 

In fact, there is so far little new evidence that has really been brought to the table on either the spillover or lab leak theories, WHO sources told Health Policy Watch. These sources stressed that the report remains preliminary in nature and that a final version may hopefully include more definitive information. 

China, Russia and Brazil object to further studies on lab escape studies 

While the report recommends further research into whether a lab biosafety failure could have triggered the SARS-CoV2 outbreak – it also admits, in roundabout diplomatic language, that the prospects for obtaining key information from China on biosafety conditions at the Wuhan Institute of Virology that studied bat coronaviruses in Wuhan, that remain  dim. 

“To support biosafety and biosecurity investigations into the introduction of SARS-CoV-2 into the human population through a laboratory incident; the SAGO notes that there would need to be access to and review of the evidence of all laboratory activities (both in vitro and in vivo studies) with coronaviruses including SARS-CoV-2-related viruses or close ancestors, and the laboratory’s approach to implementation and improvement of laboratory biosafety and biosecurity,” the report states. 

“As it is not common practice to publish the institutional implementation of biosafety and biosecurity practices of individual laboratories in peer-reviewed scientific journals, additional information will need to be obtained and reviewed to make conclusive recommendations.”

Notably, the SAGO team’s three scientists from China, Russia and Brazil, objected to further pursuit of the lab escape theory, as reported in a footnote that states: 

“Dr Vladimir Dedkov, Dr Carlos Morel, Professor Yungui Yang do not agree with the inclusion of further studies evaluating the possibility of introduction of SARS-CoV-2 to the human population through a laboratory incident in this preliminary report due to the fact that from their viewpoint, there is no new scientific evidence to question the conclusion of the WHO-convened global study of origins of SARS-CoV-2: China Part mission report published in March 2021.”

Battle between spillover versus lab escape adherents in scientific circles 

lab leak
Seafood and fresh food market in Wuhan, Hubei, China. Most confirmed cases of SARS-CoV2 were traced back to Huanan Wholesale Seafood Market.

Outside of the SAGO group – a fierce battle also continues to rage over the merits of the “lab escape” versus “natural spillover” theories. 

And if anything the new report only seemed to fan the flames of arguments on both sides – with adherents to one theory or the other facing off in the media over the merits of the report.

Experts urging more attention to the natural spillover theory lamented that the WHO report did not seem to give enough credit to recent studies of SARS-CoV2 samples found in the Huanan Seafood Wholesale Market, which have been published, but not yet peer-reviewed. 

“I think if you read our pre-prints and understand the evidence, actually there’s very strong evidence that the pandemic emerged through wildlife at the Huanan market,” the lead author of two such studies, Michael Worobey of the University of Arizona, was quoted as saying. 

Worobey and his colleagues pieced together the genetic evidence about the virus’ presence and evolution in studies of Wuhan residents in early 2020 as well as analysis of environmental samples taken from Wuhan’s live animal markets between December 2019 and February 2020. Some of those environmental samples showed high levels of SARS-CoV2 in areas in and around the cages of racoon dogs, being sold for slaughter – although no “Animal X” was identified. And critics also have said the sample size is too small to be conclusive. 

Lab biosafety advocates express satisfaction with report’s findings

On the other side of the fence, Richard H Ebright, a scientist at Rutgers University an advocate of further research on the potential biosafety failures, welcomed the new WHO report’s balance, telling Health Policy Watch: 

“The SAGO report concludes that, based on available data, it is not possible to determine whether SARS-CoV-2 entered humans through natural spillover or through research-related spillover.

“This conclusion will be anathema to those who have falsely claimed over the last two years that science shows SARS-CoV-2 entered humans through natural spillover.”

Ebright also welcomed the report’s call for “strengthening of regulation of biosafety, biosecurity, and biorisk management for pathogens research, with special attention to regulation of gain-of-function research” as part of a broader Global Framework to prevent future pathogen risks from emerging.  

“The recommendations on strengthening of regulation in the SAGO report  closely track those of a second WHO report that was released just over a week ago, that has gotten no news coverage,” he added. 

Missing gene sequence data and phylogenetic studies also under debate 

Partisans of further research into a possible biosafety failure also have pointed to SARS-CoV2 gene sequence data “deleted” by Chinese researchers early on in the pandemic from a US National Institutes of Health database as evidence of a possible cover-up.  

And recent phylogenetic studies of the virus’ family tree don’t necessarily correlate with a narrative of an initial natural spillover from animals to humans in Wuhan’s markets either, the critics say – although that claim is hotly disputed by Worobey.   

Said Jesse Bloom, a virologist with the Seattle-based Fred Hutch Research Institute: 

“I still think, (1) early COVID-19 case & sequence data that have been released by the Chinese government are likely incomplete; 

(2) for this reason, the origin of human #SARSCoV2 in Wuhan remains unclear.” 

Framework for Way Forward 

In light of the barriers faced in obtaining more original data from Chinese government sources relevant to either the lab leak or natural spillover narratives, the most constructive role that the SAGO group may have to play going forward could be in  the synthesis of  work by virus hunting scientists around the world.

The report also strikes a forward-looking note, etching out a broad “Global Framework” for how scientists should take forward research into practices and policies along the whole chain of l risks, from food safety to lab security – all critical in preventing future pandemics. 

That new framework should include:   

  • Studies of zoonotic  risks in animal groups and marketplaces;
  • Reviews of existing legislation and governance mechanisms related to lab biosafety;
  • Studies of epidemiological samples of human patients, including blood and viral samples. 

Concluded Bloom: “Continuing to openly study the possible origins of the virus is crucial both for the sake of science itself, and to design strategies to mitigate the future risks of both zoonotic and lab-based outbreaks.”   

Image Credits: dietertimmerman, abhijeet jagtap/Flickr, Arend Kuester/Flickr.

african lab
Pros Quarraisha Abdool Karim explains how to use an applicator

Africa has the scientific and intellectual capital to develop new interventions to tackle global health challenges. Particularly when local problems emerge, surely local research is the best path towards a solution. But pursuing this path requires funding that will support and promote the growth and expertise of Africa’s scientists. 

Africa is plagued by many epidemics — from tuberculosis and HIV/AIDS to malaria and wild polio — but the continent has also worked for decades to fight these threats. The key to beating these deadly diseases is turning inward to existing expertise and finding locally driven solutions.

The recent COVID-19 pandemic has placed public health back in the global spotlight and has also served as a reminder that science is not undertaken in an ivory tower. Science shapes humanity because it takes place among us. COVID-19 has also showcased that no epidemic takes place in isolation. Through collaboration, we can build on the foundations of our knowledge to bring forward innovative ways to address health challenges that benefit all of humanity.

This is not a new idea. In fact, it is something that we became all too familiar with during the AIDS pandemic.

From despair, pain and loss to transformational research

Despair, pain, and loss were rampant during the 1980s and early 1990s, at the beginning of South Africa’s HIV epidemic. Every weekend, white funeral tents in rural KwaZulu-Natal seemed to mushroom up and multiply, signifying the growing toll the virus was taking on the country.

Witnessing this helped catalyse me to undertake one of the earliest population-based studies that looked closely at this emerging health issue in South Africa. HIV prevalence was low at the time, with less than 1% of the population having been infected.

But lurking within the data was a shocking revelation: young women (15-24 years old) were six times more likely to be infected compared to their male counterparts.

We knew something had to be done. That meant understanding what had led to this striking disparity in risk. So, we began speaking to women from all parts of society to try and get a better sense of what they were experiencing. 

Power dynamics of relationships disrupting disease prevention

Here’s what we learned: power dynamics of relationships and sex were disrupting disease prevention. Women didn’t have the ability to protect themselves because of the limited options available to them — options like condoms, that placed the responsibility of reducing risk in the hands of men.

 Meanwhile, cases continued to surge in South Africa at an alarming rate, doubling annually in the general population.

Existing methods to prevent HIV infection weren’t going to cut it. Approaches designed in the global North were never going to be able to fully account for the needs of women in Africa. That’s why new solutions had to be brought forward instead.

Tenofovir: pathfinding protection from infection 

One way that we sought to empower women was through a gel that contained Tenofovir, an antiretroviral (ARV) medication. This innovative approach, shown in the CAPRISA 004 trial, enabled HIV-negative women to protect themselves from the virus. CAPRISA’s research on PrEP was recently recognised by the  VinFuture Prize as a lifesaving innovation from the global South. 

Today, Tenofovir is taken daily as a pill for HIV prevention, a solution also known as pre-exposure prophylaxis (PrEP). It has been adopted by the World Health Organization (WHO) as a key prevention option for both women and men.

And it hasn’t stopped there — a range of new anti-retroviral drugs and long-acting formulations, delivered as injections and implants, are currently being evaluated to expand prevention choices.

AIDS is no longer a fatal condition, instead it is chronic yet manageable. But we still see too many deaths and new HIV infections, particularly in marginalized populations. Two-thirds of all people living with HIV/AIDS are in sub–Saharan Africa and the region accounts for 60% of all new infections.

Saving the gains made in HIV 

As we turn our focus towards other pandemics, such as COVID-19, we cannot afford to lose the gains made in HIV. It is a trap we fell into before — when early HIV work overshadowed TB efforts — and it is not one we can afford to be caught in again.

Even now, COVID-19 continues to draw on lessons from the decades of work that have been poured into our HIV/AIDS response. This includes leveraging existing testing tools to detect COVID, utilising clinical trial infrastructure to expedite vaccine development, calling on community engagement processes to educate the public, and relying on scientific expertise to guide governments in their response.

The AIDS pandemic has taught us that scientists, policy-makers, and civil societies cannot work in a vacuum. There must be a unity of purpose that galvanises the steadfast support of global leaders in governments and funding agencies across the world.

Africa has the scientific leadership and intellectual capital to develop new technologies and interventions. This is something we have shown time and time again. If there is a problem, then local research is surely the best path toward finding a solution.

Pursuing this path of innovation requires funding that will support and promote the growth and expertise of Africa’s scientists. Our inter-dependency and shared vulnerability underscores the importance of collaboration and resource-sharing both globally and regionally that must be used for the benefit of humanity. There is no time for complacency. We must ensure that solutions are tailored by local research to best benefit those in need.

Quarraisha Abdool Karim

Professor Quarraisha Abdool Karim is an infectious diseases epidemiologist and Associate Scientific Director of the Centre for the AIDS Programme of Research in South Africa (CAPRISA). A researcher of HIV/AIDS, she  played a key role in the development of pre-exposure prophylaxis (PrEP), a daily pill to prevent HIV. Professor Abdool Karim was a 2021 Laureate of the VinFuture Prize, in the ‘Innovators from developing countries’ category.

Image Credits: CAPRISA.